Please login to the form below

Not currently logged in
Email:
Password:

flu vaccine

This page shows the latest flu vaccine news and features for those working in and with pharma, biotech and healthcare.

MHRA to fast-track vaccines modified for new COVID-19 variants

MHRA to fast-track vaccines modified for new COVID-19 variants

The MHRA says this approach is ‘tried and tested’, as it is the same process used for the seasonal flu vaccine, which requires annual modifications. ... A number of vaccine makers are working on modified vaccines to address new and emerging variants.

Latest news

  • Don't hesitate, vaccinate! Don't hesitate, vaccinate!

    And of course, not having a COVID-19 vaccine may mean they also won’t have the flu vaccine, or get their children vaccinated, meaning the negative impact proliferates. ... So, it is worth at least trying to address the concerns of vaccine hesitaters.

  • UK and CureVac to jointly develop vaccines against COVID-19 variants UK and CureVac to jointly develop vaccines against COVID-19 variants

    Agreement will utilise UK’s expertise in genomics and CureVac’s experience in mRNA vaccine development. ... Because these mRNA vaccines can be rapidly adapted we will be ready to respond swiftly to new strains and update vaccines in the same way the

  • Sanofi’s quadrivalent flu vaccine Supemtek scores EU approval Sanofi’s quadrivalent flu vaccine Supemtek scores EU approval

    Company expects first EU launches in 2022/2023 flu season. The European Commission has approved Sanofi’s quadrivalent recombinant influenza vaccine Supemtek for the prevention of flu in adults aged 18 ... Preclinical studies of the flu vaccine,

  • Sanofi, GSK to launch human trials of COVID-19 vaccine Sanofi, GSK to launch human trials of COVID-19 vaccine

    The vaccine combines Sanofi’s baculovirus expression system, which is already used in its quadrivalent flu vaccine, and GSK’s AS03 adjuvant, which is designed to boost immune responses in participants. ... In July, the UK government agreed a deal

  • UK government and GSK/Sanofi sign COVID-19 vaccine supply deal UK government and GSK/Sanofi sign COVID-19 vaccine supply deal

    The agreement covers a vaccine candidate which uses GSK’s AS03 adjuvant and is based on Sanofi’s baculovirus expression system – already used in its quadrivalent flu vaccine. ... Our scientists and researchers are racing to find a safe and

More from news
Approximately 5 fully matching, plus 113 partially matching documents found.

Latest Intelligence

  • How will COVID-19 affect uptake of vaccinations against other diseases? How will COVID-19 affect uptake of vaccinations against other diseases?

    In England, the health system is working to provide a free flu vaccine to 30 million people, the highest number on record. ... A newly eligible group comprising 50- to 64-year-olds will also be offered a free flu vaccine later in the season.

  • Biotech profile: Tom Evans, CEO, Vaccitech.

    The company’s most advanced programme is a universal flu vaccine, VTP-100, which has just begun phase 2b trials.Vaccitech is also developing a clinical stage therapeutic vaccine for prostate ... We need new flu vaccine products that enable long-term

  • Country report: The healthcare market in Japan Country report: The healthcare market in Japan

    It launched a new division in January 2012 to expand its vaccines business globally, testing a new vaccine to prevent Haemophilus influenzae type b and developing a human papillomavirus vaccine and ... a flu vaccine.

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics